_id
6915fe44bc934aba376b2850
Ticker
SRDX
Name
SurModics Inc
Exchange
NASDAQ
Address
9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523
Country
USA
Sector
Healthcare
Industry
Medical Devices
Currency
USD
Website
https://www.surmodics.com
Description
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Last Close
42.98
Volume
-
Current Price
42.98
Change
0
Last Updated
2025-11-24T11:56:29.012Z
Image
data:image/webp;base64,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
Ipo Date
1998-03-04T00:00:00.000Z
Market Cap
614582464
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.32730000000000004
Sentiment Sources
10
Rating
3
Target Price
43
Strong Buy
0
Buy
0
Hold
2
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
29567000
Cost Of Revenue
8576000
Gross Profit
20991000
Operating Expenses
26233000
Operating Income
-5242000
Interest Expense
865000
Pretax Income
-5929000
Net Income
-5318000
Eps
-0.37238288635249633
Dividends Per Share
-
Shares Outstanding
14281000
Income Tax Expense
-611000
EBITDA
-5242000
Operating Margin
-17.729225149660095
Total Other Income Expense Net
-687000
Cash
26281000
Short Term Investments
6447000
Receivables
25022000
Inventories
15756000
Total Current Assets
75994000
Property Plant Equipment
22840000
Total Assets
169822000
Payables
5928000
Short Term Debt
1024000
Long Term Debt
29666000
Total Liabilities
58513000
Equity
111309000
Depreciation
2103000
Change In Working Capital
3049000
Cash From Operations
1405000
Capital Expenditures
501000
Cash From Investing
-4933000
Cash From Financing
-29000
Net Change In Cash
-2902000
PE
-
PB
5.5143553531161
ROE
-4.777690932449308
ROA
-3.13151417366419
FCF
904000
Fcf Percent
0.03057462711807082
Piotroski FScore
2
Health Score
28
Deep Value Investing Score
4.5
Defensive Investing Score
6.5
Dividend Investing Score
3
Economic Moat Investing Score
5.8
Garp Investing Score
4
Growth Investing Score
3
Momentum Investing Score
4.5
Net Net Investing Score
2.5
Quality Investing Score
4
Value Investing Score
3
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
29567000
Quarters > 0 > income Statement > cost Of Revenue
8576000
Quarters > 0 > income Statement > gross Profit
20991000
Quarters > 0 > income Statement > operating Expenses
26233000
Quarters > 0 > income Statement > operating Income
-5242000
Quarters > 0 > income Statement > interest Expense
865000
Quarters > 0 > income Statement > pretax Income
-5929000
Quarters > 0 > income Statement > net Income
-5318000
Quarters > 0 > income Statement > eps
-0.37238288635249633
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
14281000
Quarters > 0 > income Statement > income Tax Expense
-611000
Quarters > 0 > income Statement > EBITDA
-5242000
Quarters > 0 > income Statement > operating Margin
-17.729225149660095
Quarters > 0 > income Statement > total Other Income Expense Net
-687000
Quarters > 0 > balance Sheet > cash
26281000
Quarters > 0 > balance Sheet > short Term Investments
6447000
Quarters > 0 > balance Sheet > receivables
25022000
Quarters > 0 > balance Sheet > inventories
15756000
Quarters > 0 > balance Sheet > total Current Assets
75994000
Quarters > 0 > balance Sheet > property Plant Equipment
22840000
Quarters > 0 > balance Sheet > total Assets
169822000
Quarters > 0 > balance Sheet > payables
5928000
Quarters > 0 > balance Sheet > short Term Debt
1024000
Quarters > 0 > balance Sheet > long Term Debt
29666000
Quarters > 0 > balance Sheet > total Liabilities
58513000
Quarters > 0 > balance Sheet > equity
111309000
Quarters > 0 > cash Flow > net Income
-5318000
Quarters > 0 > cash Flow > depreciation
2103000
Quarters > 0 > cash Flow > change In Working Capital
3049000
Quarters > 0 > cash Flow > cash From Operations
1405000
Quarters > 0 > cash Flow > capital Expenditures
501000
Quarters > 0 > cash Flow > cash From Investing
-4933000
Quarters > 0 > cash Flow > cash From Financing
-29000
Quarters > 0 > cash Flow > net Change In Cash
-2902000
Quarters > 0 > ratios > PE
-0.37238288635249633
Quarters > 0 > ratios > PB
5.5143553531161
Quarters > 0 > ratios > ROE
-4.777690932449308
Quarters > 0 > ratios > ROA
-3.13151417366419
Quarters > 0 > ratios > FCF
904000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
0.03057462711807082
Quarters > 0 > health Score
28
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
28085000
Quarters > 1 > income Statement > cost Of Revenue
7830000
Quarters > 1 > income Statement > gross Profit
20255000
Quarters > 1 > income Statement > operating Expenses
24265000
Quarters > 1 > income Statement > operating Income
-4010000
Quarters > 1 > income Statement > interest Expense
855000
Quarters > 1 > income Statement > pretax Income
-4682000
Quarters > 1 > income Statement > net Income
-5209000
Quarters > 1 > income Statement > eps
-0.3648270065835551
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
14278000
Quarters > 1 > income Statement > income Tax Expense
527000
Quarters > 1 > income Statement > EBITDA
-4010000
Quarters > 1 > income Statement > operating Margin
-14.278084386683283
Quarters > 1 > income Statement > total Other Income Expense Net
-672000
Quarters > 1 > balance Sheet > cash
29183000
Quarters > 1 > balance Sheet > short Term Investments
1965000
Quarters > 1 > balance Sheet > receivables
21391000
Quarters > 1 > balance Sheet > inventories
16060000
Quarters > 1 > balance Sheet > total Current Assets
71747000
Quarters > 1 > balance Sheet > property Plant Equipment
25889000
Quarters > 1 > balance Sheet > total Assets
163214000
Quarters > 1 > balance Sheet > payables
3387000
Quarters > 1 > balance Sheet > short Term Debt
2072000
Quarters > 1 > balance Sheet > long Term Debt
29628000
Quarters > 1 > balance Sheet > total Liabilities
52968000
Quarters > 1 > balance Sheet > equity
110246000
Quarters > 1 > cash Flow > net Income
-5209000
Quarters > 1 > cash Flow > depreciation
2139000
Quarters > 1 > cash Flow > change In Working Capital
2448000
Quarters > 1 > cash Flow > cash From Operations
949000
Quarters > 1 > cash Flow > capital Expenditures
319000
Quarters > 1 > cash Flow > cash From Investing
-2280000
Quarters > 1 > cash Flow > cash From Financing
48000
Quarters > 1 > cash Flow > net Change In Cash
-962000
Quarters > 1 > ratios > PE
-0.3648270065835551
Quarters > 1 > ratios > PB
5.566355604738494
Quarters > 1 > ratios > ROE
-4.724887977795113
Quarters > 1 > ratios > ROA
-3.1915154337250478
Quarters > 1 > ratios > FCF
630000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
0.0224319031511483
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
29922000
Quarters > 2 > income Statement > cost Of Revenue
7425000
Quarters > 2 > income Statement > gross Profit
22497000
Quarters > 2 > income Statement > operating Expenses
24978000
Quarters > 2 > income Statement > operating Income
-2481000
Quarters > 2 > income Statement > interest Expense
882000
Quarters > 2 > income Statement > pretax Income
-2944000
Quarters > 2 > income Statement > net Income
-3651000
Quarters > 2 > income Statement > eps
-0.256552596444382
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
14231000
Quarters > 2 > income Statement > income Tax Expense
707000
Quarters > 2 > income Statement > EBITDA
21000
Quarters > 2 > income Statement > operating Margin
-8.291558050932423
Quarters > 2 > income Statement > total Other Income Expense Net
-463000
Quarters > 2 > balance Sheet > cash
30145000
Quarters > 2 > balance Sheet > short Term Investments
0
Quarters > 2 > balance Sheet > receivables
22538000
Quarters > 2 > balance Sheet > inventories
15261000
Quarters > 2 > balance Sheet > total Current Assets
71849000
Quarters > 2 > balance Sheet > property Plant Equipment
23805000
Quarters > 2 > balance Sheet > total Assets
163740000
Quarters > 2 > balance Sheet > payables
2561000
Quarters > 2 > balance Sheet > short Term Debt
2098000
Quarters > 2 > balance Sheet > long Term Debt
29591000
Quarters > 2 > balance Sheet > total Liabilities
51971000
Quarters > 2 > balance Sheet > equity
111769000
Quarters > 2 > cash Flow > net Income
-3651000
Quarters > 2 > cash Flow > depreciation
2083000
Quarters > 2 > cash Flow > change In Working Capital
-8366000
Quarters > 2 > cash Flow > cash From Operations
-7894000
Quarters > 2 > cash Flow > capital Expenditures
302000
Quarters > 2 > cash Flow > cash From Investing
3698000
Quarters > 2 > cash Flow > cash From Financing
-1203000
Quarters > 2 > cash Flow > net Change In Cash
-5970000
Quarters > 2 > ratios > PE
-0.256552596444382
Quarters > 2 > ratios > PB
5.472433143358176
Quarters > 2 > ratios > ROE
-3.2665587059023524
Quarters > 2 > ratios > ROA
-2.2297544888237453
Quarters > 2 > ratios > FCF
-8196000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-0.27391217164628034
Quarters > 2 > health Score
29
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
33227000
Quarters > 3 > income Statement > cost Of Revenue
8674000
Quarters > 3 > income Statement > gross Profit
24553000
Quarters > 3 > income Statement > operating Expenses
25166000
Quarters > 3 > income Statement > operating Income
-613000
Quarters > 3 > income Statement > interest Expense
884000
Quarters > 3 > income Statement > pretax Income
-1137000
Quarters > 3 > income Statement > net Income
-3449000
Quarters > 3 > income Statement > eps
-0.24307562196067375
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
14189000
Quarters > 3 > income Statement > income Tax Expense
2312000
Quarters > 3 > income Statement > EBITDA
1002000
Quarters > 3 > income Statement > operating Margin
-1.8448851837361182
Quarters > 3 > income Statement > total Other Income Expense Net
-524000
Quarters > 3 > balance Sheet > cash
36115000
Quarters > 3 > balance Sheet > short Term Investments
3997000
Quarters > 3 > balance Sheet > receivables
23164000
Quarters > 3 > balance Sheet > inventories
15168000
Quarters > 3 > balance Sheet > total Current Assets
81304000
Quarters > 3 > balance Sheet > property Plant Equipment
27984000
Quarters > 3 > balance Sheet > total Assets
178562000
Quarters > 3 > balance Sheet > payables
2786000
Quarters > 3 > balance Sheet > short Term Debt
2080000
Quarters > 3 > balance Sheet > long Term Debt
29554000
Quarters > 3 > balance Sheet > total Liabilities
59665000
Quarters > 3 > balance Sheet > equity
118897000
Quarters > 3 > cash Flow > net Income
-3449000
Quarters > 3 > cash Flow > depreciation
2139000
Quarters > 3 > cash Flow > change In Working Capital
2783000
Quarters > 3 > cash Flow > cash From Operations
3658000
Quarters > 3 > cash Flow > capital Expenditures
542000
Quarters > 3 > cash Flow > cash From Investing
9458000
Quarters > 3 > cash Flow > cash From Financing
-1562000
Quarters > 3 > cash Flow > net Change In Cash
11814000
Quarters > 3 > ratios > PE
-0.24307562196067375
Quarters > 3 > ratios > PB
5.129172477017923
Quarters > 3 > ratios > ROE
-2.9008301302808315
Quarters > 3 > ratios > ROA
-1.9315419854168299
Quarters > 3 > ratios > FCF
3116000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.09377915550606435
Quarters > 3 > health Score
34
Valuation > metrics > PE
-0.37238288635249633
Valuation > metrics > PB
5.5143553531161
Valuation > final Score
24.856446468839
Valuation > verdict
83.8% Overvalued
Profitability > metrics > ROE
-4.777690932449308
Profitability > metrics > ROA
-6.997920888491197
Profitability > metrics > Net Margin
-0.1798626847498901
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.5256807625618773
Risk > metrics > Interest Coverage
-6.060115606936416
Risk > final Score
24
Risk > verdict
High
Liquidity > metrics > Current Ratio
10.931242807825086
Liquidity > metrics > Quick Ratio
8.664844649021864
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
24.336443952615063
Prev Valuations > 1
25.275668566418243
Prev Valuations > 2
28.708275229820774
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
41
Prev Risks > 1
49
Prev Risks > 2
45
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-12T01:07:54.348Z
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AGroupe la Francaise Sells 33,700 Shares of Surmodics, Inc. $SRDX Defense World
Read more →Why analysts upgrade SRDX stock - July 2025 Highlights & Free Reliable Trade Execution Plans moha.gov.vn
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
HOLD
Target Price:
$43
Analyst Picks
Strong Buy
0
Buy
0
Hold
2
Sell
0
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 62.12% of the total shares of SurModics Inc
1.
BlackRock Inc(8.0243%)
since
2025/06/30
2.
AllianceBernstein L.P.(5.9483%)
since
2025/06/30
3.
Vanguard Group Inc(5.6666%)
since
2025/06/30
4.
Soleus Capital Management, L.P.(5.5188%)
since
2025/06/30
5.
Morgan Stanley - Brokerage Accounts(4.5868%)
since
2025/06/30
6.
Readystate Asset Management LP(3.0328%)
since
2025/06/30
7.
UBS Group AG(2.9566%)
since
2025/06/30
8.
Gabelli Funds LLC(2.9014%)
since
2025/06/30
9.
Hudson Bay Capital Management LP(2.7977%)
since
2025/06/30
10.
Qube Research & Technologies(2.7556%)
since
2025/06/30
11.
Dimensional Fund Advisors, Inc.(2.4775%)
since
2025/06/30
12.
Geode Capital Management, LLC(2.3517%)
since
2025/06/30
13.
State Street Corp(2.2443%)
since
2025/06/30
14.
Balyasny Asset Management LLC(1.9002%)
since
2025/06/30
15.
ODDO BHF Asset Management SAS(1.8751%)
since
2025/06/30
16.
HSBC Holdings PLC(1.866%)
since
2025/06/30
17.
Goldman Sachs Group Inc(1.6076%)
since
2025/06/30
18.
Gabelli Securities Inc(1.4239%)
since
2025/06/30
19.
Cnh Partners, LLC(1.0923%)
since
2025/06/30
20.
Millennium Management LLC(1.0884%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.